Literature DB >> 7630216

Long-term suppressive therapy for Candida parapsilosis-induced prosthetic valve endocarditis.

L M Baddour1.   

Abstract

Prompt valve replacement is advocated in patients in whom candidal prosthetic valve endocarditis develops. Unfortunately, some patients with this condition are considered nonsurgical candidates, and they are unable to tolerate long-term administration of amphotericin B with or without flucytosine. Herein we describe a patient with Candida parapsilosis-induced prosthetic valve endocarditis in whom oral administration of fluconazole during an 11-month period successfully suppressed the fungal infection. Three previously published cases indicate that long-term noncurative suppressive therapy for C. parapsilosis-induced prosthetic valve endocarditis may allow prolonged symptom-free survival for such patients.

Entities:  

Mesh:

Year:  1995        PMID: 7630216     DOI: 10.4065/70.8.773

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  5 in total

1.  Candida endocarditis: the insidious killer.

Authors:  Vithiya Ganesan; Gowdara Shankarappa Vijay Kumar; Shunmuga Sundaram Ponnusamy
Journal:  J Glob Infect Dis       Date:  2015 Jan-Mar

Review 2.  Candida parapsilosis, an emerging fungal pathogen.

Authors:  David Trofa; Attila Gácser; Joshua D Nosanchuk
Journal:  Clin Microbiol Rev       Date:  2008-10       Impact factor: 26.132

3.  Prosthetic valve endocarditis due to Candida albicans treated successfully with medical treatment alone.

Authors:  Manabu Noguchi; Hideaki Takai; Kiyoyuki Eishi; Sunao Atogami
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2004-06

Review 4.  Management of invasive candidiasis in critically ill patients.

Authors:  Stijn Blot; Koenraad Vandewoude
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 5.  Candida parapsilosis endocarditis: a comparative review of the literature.

Authors:  C Garzoni; V A Nobre; J Garbino
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-12       Impact factor: 3.267

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.